![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » MEDTRONIC RECEIVES FDA APPROVAL FOR GUARDIAN REAL-TIME CONTINUOUS GLUCOSE MONITORING SYSTEM
MEDTRONIC RECEIVES FDA APPROVAL FOR GUARDIAN REAL-TIME CONTINUOUS GLUCOSE MONITORING SYSTEM
Medtronic, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardian(R) REAL-Time System, a doctor-prescribed continuous glucose monitoring (CGM) system for improved diabetes management. Especially well suited for diabetes
patients who frequently monitor their glucose levels, the Guardian REAL-Time System
is intended to help protect patients by alerting users to high and low glucose
levels. The REAL-Time information and retrospective glucose trend data provided
by the Guardian REAL-Time System are designed to help patients more tightly control
glucose levels. Improved glucose control has been shown to significantly reduce
the likelihood of certain long-term complications, including blindness, kidney
failure, amputation, impotence, and heart disease. The system will be available
nationwide by the end of this year.
Business
Wire
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct